Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin for Growth Hormone Secretion in PCOS
NCT02122380Phase 4
Key facts
- Status
- Completed
- Start
- Feb 2016
- Primary completion
- Aug 2019
- Countries
- 1
- Sponsor
- Vanderbilt University
- Modality
- Small Molecules
- Drugs
- sitagliptin
- Conditions
- polycystic ovary syndrome (PCOS)
01
Overview
Phase 4, randomised, double-blind trial of sitagliptin in polycystic ovary syndrome (PCOS), sponsored by Vanderbilt University. Started Feb 2016; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Registry description
Adults with abdominal obesity are at high risk for cardiovascular disease and also exhibit diminished growth hormone (GH) secretion; the latter further contributes to the development of visceral adiposity, impaired fibrinolysis and inflammation.Growth hormone releasing hormone (GHRH), the primary stimulus for endogenous GH secretion, is a substrate of dipeptidyl peptidase 4 (DPP4); inhibition of DPP4 with the currently available anti-diabetic therapy, sitagliptin, may therefore increase GH secretion by decreasing the degradation of GHRH. The proposed research will test the hypothesis that…
Beyond the preview
Go deeper on NCT02122380.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02122380.